ebvint cell
Cell therapyexperimental
Clinical trial activity
1 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 14, 2018 (NCT03789617)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- epstein-barr virusImmunity, passive
epstein-barr virus immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03789617 | Phase 1/Phase 2 (Phase 2) | Dec 14, 2018 | Catholic University of Korea, Chonnam National University, Eutilex, Inje University, Kyungpook University, Pusan National University, Sungkyunkwan University, The National Cancer Center |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Catholic University of Korea | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Chonnam National University | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Eutilex | For profit | 1 | 1 | 1 | 2018 |
| Inje University | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Kyungpook University | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Pusan National University | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Sungkyunkwan University | Academic/Hospital | 1 | 0 | 1 | 2018 |
| The National Cancer Center | Academic/Hospital | 1 | 0 | 1 | 2018 |
8 organizations
Page 1 / 1